Overexpression of the Catalytically Impaired Taspase1T234V or Taspase1D233A Variants Does Not Have a Dominant Negative Effect in T(4;11) Leukemia Cells by Bier, Carolin et al.
Overexpression of the Catalytically Impaired
Taspase1
T234V or Taspase1
D233A Variants Does Not Have
a Dominant Negative Effect in T(4;11) Leukemia Cells
Carolin Bier
1*, Rouven Hecht
2, Lena Kunst
2, Sabine Scheiding
3,D e ´sire ´eW u ¨nsch
1, Dorothe ´e Goesswein
1,
Gu ¨nter Schneider
4, Oliver H. Kra ¨mer
3, Shirley K. Knauer
2*, Roland H. Stauber
1*
1Molecular and Cellular Oncology, Mainz Screening Center (MSC), University Hospital of Mainz, Mainz, Germany, 2Institute for Molecular Biology, Center for Medical
Biotechnology (ZMB), University Duisburg-Essen, Essen, Germany, 3Institute for Biochemistry and Biophysics/Centre for Molecular Biomedicine (CMB), Friedrich-Schiller-
University Jena, Jena, Germany, 4Department of Internal Medicine II, Technical University of Munich, Munich, Germany
Abstract
Background: The chromosomal translocation t(4;11)(q21;q23) is associated with high-risk acute lymphoblastic leukemia of
infants. The resulting AF4NMLL oncoprotein becomes activated by Taspase1 hydrolysis and is considered to promote
oncogenic transcriptional activation. Hence, Taspase1’s proteolytic activity is a critical step in AF4NMLL pathophysiology. The
Taspase1 proenzyme is autoproteolytically processed in its subunits and is assumed to assemble into an abba-heterodimer,
the active protease. Therefore, we investigated here whether overexpression of catalytically inactive Taspase1 variants are
able to interfere with the proteolytic activity of the wild type enzyme in AF4NMLL model systems.
Methodology/Findings: The consequences of overexpressing the catalytically dead Taspase1 mutant, Taspase1
T234V, or the
highly attenuated variant, Taspase1
D233A, on Taspase1’s processing of AF4NMLL and of other Taspase1 targets was analyzed
in living cancer cells employing an optimized cell-based assay. Notably, even a nine-fold overexpression of the respective
Taspase1 mutants neither inhibited Taspase1’s cis- nor trans-cleavage activity in vivo. Likewise, enforced expression of the a-
or b-subunits showed no trans-dominant effect against the ectopically or endogenously expressed enzyme. Notably, co-
expression of the individual a- and b-subunits did not result in their assembly into an enzymatically active protease
complex. Probing Taspase1 multimerization in living cells by a translocation-based protein interaction assay as well as by
biochemical methods indicated that the inactive Taspase1 failed to assemble into stable heterocomplexes with the wild
type enzyme.
Conclusions: Collectively, our results demonstrate that inefficient heterodimerization appears to be the mechanism by
which inactive Taspase1 variants fail to inhibit wild type Taspase1’s activity in trans. Our work favours strategies targeting
Taspase1’s catalytic activity rather than attempts to block the formation of active Taspase1 dimers to interfere with the
pathobiological function of AF4NMLL.
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Introduction
Chromosomal rearrangements of the mixed lineage leukemia
(MLL) gene with numerous partner genes are frequently found in
acute myeloid (AML) and acute lymphoblastic leukemia (ALL)
[1,2]. Fused on chromosome4 (AF4) is the most common
translocation partner in MLL-mediated leukemia, resulting in
the expression of the AF4NMLL and MLLNAF4 fusion proteins.
Although the pathomechanism of t(4;11)-mediated leukemia is still
discussed controversially, expression of the AF4NMLL fusion
enhanced the hematopoietic repopulating potential of CD34
+
cells, and led to the development of predominantly proB ALL in a
mouse model [2,3]. Similar to the prototypic MLL protein, the
AF4NMLL fusion protein contains cleavage-sites for Threonine
Aspartase 1 (Taspase1, Tasp) and, is considered a bona fide
substrate for this protease [4,5,6,7,8].
In leukemic cells, the unprocessed AF4NMLL fusion protein is a
substrate for the E3-ubiquitin ligases SIAH1 and SIAH2 [9,10].
SIAH1 and SIAH2, belonging to the family of the seven in
absentia homolog (SIAH), are E3 ligases involved in ubiquitination
and proteasome-mediated degradation of specific proteins [9,10].
Therefore the presence of these ligases leads to a low steady-state
level of the AF4NMLL fusion, hampering its detection and
experimental analysis. However, following its proteolytic process-
ing by Taspase1, the AF4NMLL cleavage products AF4NMLL.N
and MLL.C heterodimerize through their FYRN and FYRC
interaction domains, forming a high molecular-weight protein
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e34142complex resistant to SIAH-mediated degradation [9,10]. Thus,
chemico-genetic interference with Taspase1’s activity is expected
to promote AF4NMLL degradation, thereby precluding the
activation of oncogenic programs and disease development.
Moreover, a total of at least 64 MLL chromosomal-fusion partners
have been characterized so far at the molecular level, associated
with disease (Table S1) [1,11,12]. Hence, Taspase1’s proteolytic
processing of MLL fusions in general may contribute to various
pathologies.
The human Taspase1 gene encodes a protein of 420 amino
acids (aa) and is able to cleave other substrates in trans by
recognizing a conserved peptide motif
(Q
3[F,I,L,V]
2D
1QG
1’x
2’D
3’D
4’) with an aspartate at the P1
position [6,7]. The discovery of Taspase1 founded a new class of
endopeptidases that utilize the N-terminal threonine of its mature
b-subunit as the active site, which is generated by autoproteolysis
of the proenzyme (cis-cleavage) [6]. Mutation of the catalytic
nucleophile, Thr
234, completely abolishes Taspase1’s catalytic
activity [6,13]. Based on data mainly derived from analyzing
bacterially expressed Taspase1, it is assumed that the proenzyme
assembles into an asymmetric abba-heterodimer following
autoproteolysis, representing the active protease [6,13].
Protein-protein interactions (PPIs) in general are key players for
multiple (patho)biological cellular processes [14]. Thus, interfering
with disease-relevant interactomes via enforced expression of
dominant-negative mutants and/or small molecules has emerged
as a promising, though challenging strategy for human therapeu-
tics [15,16]. Blocking the p53-mdm2 interaction with synthetic
molecules had been shown to induce p53 activation and thereof
tumor cell death [17]. Likewise, the peptide-mediated disruption
of the AF4–AF9 protein complex, or targeting the oligomerization
domain of RUNX1/ETO interfered with the activity of the fusion
proteins in leukemic cells [18,19]. Recently, we also showed that it
is in principle possible to specifically inhibit and to destroy the
AF4NMLL oncoprotein by genetic PPIs inhibitors [9].
Consequently, as currently no effective synthetic Taspase1
inhibitors are available, we here investigated whether selectively
interfering with the formation of the proposed active Taspase1
abba-heterodimer would block processing of the AF4NMLL fusion
and thus, may prevent leukemogenesis [20,21]. Studies investigat-
ing the biological consequences of overexpressing inactive
Taspase1 variants have not been performed before. Hence we
here developed and employed novel cell-based assays allowing to
functionally monitor the effects of overexpressing catalytically
inactive or attenuated Taspase1 mutants on Taspase1’s processing
of AF4NMLL in living cancer cells in real time. To our knowledge,
this is the first comprehensive study addressing Taspase1 multi-
merization and genetic interference thereof in vivo.
Materials and Methods
Antibodies (Ab), Reagents and Compounds
Ab used: anti-(a)-GapDH (Glyceraldehyde-3-phosphate dehy-
drogenase, sc-47724; Santa Cruz Biotechnology, Heidelberg,
Germany); a-GFP (green fluorescent protein, sc-8334; Santa Cruz
Biotechnology, Heidelberg, Germany); a-GST (glutathione S-
transferase, sc-57753; Santa Cruz Biotechnology, Heidelberg,
Germany); a-NPM1 (nucleophosmin, #3542 Cell Signaling); a-
TaspC (directed against the C-terminus of Taspase1, AP1330b
BioCat GmbH, Heidelberg, Germany); a-TaspN (directed against
the N-terminus of Taspase1, sc-85945; Santa Cruz Biotechnology,
Heidelberg, Germany). Appropriate HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology, Heidelberg, Germany)
were used.
Plasmids
AF4NMLL, transcription factor IIA (TFIIA) and upstream
stimulatory factor2 (USF2) indicator protein expression plasmids
were derived from pNLS-GFP/GST-CS3-RevNES (pCasp3-
Clev), encoding a fusion composed of the SV40 large T-antigen
nuclear localization signal (NLS), GST, GFP, the Caspase3
cleavage site (CS3), and a strong nuclear export signal (NES) of
the human immunodeficiency virus type 1 (HIV-1) Rev protein.
[7,22] In p_NLS-GFP/GST-AF4NMLL_S1/2-NESRev
(pANM_S1/2), p_NLS-GFP/GST-AF4NMLL_S1-NESRev
(pANM_S1) and p_NLS-GFP/GST-AF4NMLL_S2-NESRev
(pANM_S2), CS3 was replaced by the Taspase1 cleavage site from
AF4NMLL (S1/2 – both cleavage sites aa 1582–1710; S1 – first
cleavage site:
1600AEGQVDGADD
1609; S2 – second cleavage site:
1652KISQLDGVDD
1661), as well as by a GSGS linker following
the cleavage site. To determine the linker sequences allowing
optimal processing by Taspase1, plasmids containing the sequenc-
es
1655QLDGVDD
1661, GSGS
1655QLDGVDD
1661 or
1652KISQLDGVDD
1661G were established likewise. pANM_S1mut
and pANM_S2mut encode fusions containing mutated Taspase1
cleavage sites, in which P1 and P1’ were exchanged by alanin
(S1mut:
1600AEGQVAAADD
1609 and S2mut:
1652KISQ-
LAAVDD
1661), precluding their processing by Taspase1.
pTFIIA_S, pUSF2_S, pTFIIA-GFP and pUSF2-GFP were
described. [7] Besides the plasmids expressing green fluorescent
protein fusions, we also constructed versions in which GFP was
replaced by the red-fluorescent protein mCherry or RFP allowing
performing dual- or triple-color in vivo assays.
Expression constructs encoding untagged Taspase1, Taspase1
fusion with autofluorescent proteins, including the red-fluorescent
protein mCherry, a cytoplasmatic version of GFP-tagged Taspase1
(pTaspcyt), and NPM1 as untagged or fusions with autofluorescent
proteins were described. [7,23] Expression constructs encoding
Taspase1 as a fusion with the small HA-tag was generated as
described. [9,24] The Taspase1 expression plasmid was used as
template to amplify the Taspase1 a- and b-subunits. Cloning of
the subunits into expression vectors pc3-GFP and pc3-BFP using
BamHI/NheI-restriction sites, respectively, allowed the expression
of Taspase1 subunits as fusions with green and blue fluorescent
proteins as described. [25] A cytoplasmatic version of a GFP-
tagged Taspase1 b-subunit is encoded by pTasp-bCyt, which was
described. [20] Plasmids pTasp
T234V- and pTasp
D233A-GFP/-
mCherry/-BFP or their untagged versions were generated by
splice overlap extension PCR as reported. [7] pRevM10BL-RFP
was generated by replacing BFP by RFP in RevM10BL-BFP using
NheI- and EcoRI-restriction sites. pF143 encoding GFP, F145
encoding BFP and pBluescript (BSK) were described. [23,26]
Bacterial expression plasmids pGEX_GST-Tasp-GFP and
pGEX_GST-GFP were described. [20] A detailed overview of
plasmids and oligonucleotides used for PCR amplification and
cloning can be found in Table S2 and S3.
Cells, Transfection and Microscopy
Leukemic and solid cancer cell lines used in the study were
maintained and transfected as described [9,23]. Observation and
image analysis of living or fixed cells were performed as described
[7,27]. To determine the average intracellular protein localization,
at least 200 fluorescent cells from three separate images were
examined in three independent experiments, and representative
images are shown. The number of cells exhibiting cytoplasmic (C;
cytoplasmic signal .80% of the total cellular signal), cytoplasmic
and nuclear (C/N), or nuclear (N; nuclear signal .80% of the
total cellular signal) fluorescence was counted. As standards for this
semiquantitative determination, the total cellular BFP (blue), GFP
Genetic Taspase1 Targeting
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calculating the integrated pixel intensity in the imaged cell
multiplied by the area of the cell in 100 fluorescent cells using a
digital AxioCam CCD camera (Carl Zeiss, Jena, Germany) as
described [7,27]. The nuclear signal was similarly obtained by
measuring the pixel intensity in the respective nuclei. Nuclei were
marked by Hoechst 33258 staining as described [20,27].
Criteria for efficient in vivo protein interaction using the protein
interaction assay was that in .80% of 200 mCherry- and GFP-
positive cells, mCherry and GFP co-localized at the nucleolus. Co-
localization was further quantitated by confocal laser scanning
microscopy using the ‘‘Overlap coefficient according to Manders’’
co-localization algorithm as described [24,27]. Colocalization
coefficients represent ‘‘Overlap coefficient according to Manders’’
[9,24,27]. R~
P
i S1i S2i ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
i (S1i)
2 (S2i)
2 p R represents the calculated overlap
coefficient, S1 and S2 the measured signal in the two channels, and
i a specific pixel of the taken image. Therefore, the calculated R
value indicates an overlap of the signals and thus represents the
true degree of colocalization. Other presented coefficients
resembling Pearson’s correlation coefficient Rr. Overlap coeffi-
cients k1 and k2 and colocalization coefficients m1 and m2 were
described [27,28].
Protein Extraction and Immunoblot Analysis
Preparation of whole lysates from cells and immunoblotting
were carried out as described [23]. Equal loading of lysates was
controlled by reprobing blots for GapDH as described [7].
Gel Filtration Chromatography
MV4;11 cells were harvested by centrifugation at 350ug, 4uC,
5umin, washed with ice-cold phosphate-buffered saline and lysed
by the addition of NETN buffer (100 mM NaCl; 10 mM Tris,
pH 8; 10% Glycerol; 1 mM EDTA; 0.5% v/v NP40; 1 mM
DTT; 1 mM PMSF; 1 fold Complete Protease Inhibitor – Roche,
Germany) as described in [7]. After sonication lysates were
centrifuged (14.000 rpm, 4uC, 30 min) and supernatant filtered
(micro-centrifuge-filtered tubes 0.2 mm – Laborservice Onken
GmbH) prior to gel filtration chromatography. The extracts were
fractionated using size exclusion chromatography with Superose-6
10/300 GL columns (GE Healthcare FPLC system, optimal
separation range from 3 MDa to 5 kDa). For system calibration
purified aprotinin (6.5 kDa), ribunclease A (13.7 kDa), carbonic
anhydrase (29 kDa) and ovalbumin (44 kDa) were purchased from
Sigma Aldrich (Sigma Aldrich, Munich, Germany) and used as
standards. Loading and elution of the FPLC system was carried
out in 50 mM Phosphate with 0.15 M NaCl pH 7. 500 ml
fractions were collected and stored at 270uC until analyzed by
SDS-PAGE as described [29].
Immunoprecipitation (IP)
IP of GFP-tagged proteins was performed using a-GFP magnetic
beads and m-MACS columns (MiltenyiBiotec, Bergisch Gladbach,
Germany) [7,20]. Briefly, whole cell lysates were incubated with
50 ml a-GFP magnetic beads for 30 min on ice. Lysates with
magnetic beads were applied onto the columns, washed, 20 ml
elution buffer was applied and incubated for 5 min. To complete
protein elution, 50 ml elution buffer were applied. 30 ml of the
eluate, as well as 3% of input were analyzed as outlined [23].
Statistical Analysis
For experiments stating p-values, a paired Student’s t-test was
performed. Unless stated otherwise, p-values represent data
obtained from three independent experiments done in triplicate.
p-values ,0.05 were considered significant [23].
Results
Monitoring Taspase1 Processing of AF4NMLL Substrates
in Living Cells
As the AF4NMLL fusion is a substrate for SIAH1/SIAH2, its
steady-state level is low, thereby hampering its detection and
experimental analysis [8]. In fact, studies visualizing the intracel-
lular localization of uncleaved or processed AF4NMLL protein are
still missing [3]. Also, as biochemical data and in vitro interference
strategies must be effective at the cellular level, they have to be
verified in vivo. Hence, we set out to establish a suitable cell-based
assay in the most relevant test tube, the living cell (Figure 1).
To analyze Taspase1’s processing of AF4NMLL substrates in
living cells, we exploited a two component autofluorescent
indicator protein system [22]. Therefore, the AF4NMLL residues
surrounding the two Taspase1 cleavage sites (ANM_S1/2: aa
1582–1710 of the AF4NMLL fusion protein) were inserted into a
backbone composed of GST, GFP, a N-terminal nuclear import
(NLS) and a C-terminal nuclear export signal (NES) (Figure 1a).
As second element the Taspase1 open reading frame was cloned
from the Taspase1-expressing acute monocytic leukemia (AMoL)
cell lines MV4;11 and THP-1, carrying a t(4;11) or t(9;11)
translocation, respectively. Both sequences are identical to the one
described by Hsieh et al. [6]. The rationale of this specific assay
set-up was that the resulting NLS-GFP/GST-AF4NMLL_S1/2-
NES fusion protein (ANM_S1/2) localizes predominantly to the
cytoplasm, whereas Taspase1-mediated cleavage liberates the NES
triggering nuclear accumulation (Figure 1b). However, due to the
presence of two cleavage-sites, the ANM_S1/2 indicator protein
was already (partially) cleaved by endogenous Taspase1
(Figure 1c), which was especially evident in cell lines with high
protease expression levels (Figure S1a).
As this efficient processing precludes the use of the indicator
protein in its current set-up, we engineered proteins harboring
only individual AF4NMLL cleavage sites, ANM_S1 (
1600AEGQVD-
GADD
1609)o rA NM_S2 (
1652KISQLDGVDD
1661), which are
expected to be less efficiently processed. As shown in Figure
S1b–e, we found that the addition of a linker sequence was crucial
for the performance of the ANM_S1 and ANM_S2 indicator
proteins. Both indicator proteins localize predominantly to the
cytoplasm in cancer cells, whereas ectopic expression of biolog-
ically active Taspase1 promoted their cleavage and complete
nuclear accumulation (Figure 1d). As a control, constructs
containing non-functional Taspase1 cleavage sites (ANM_S1mut,
aa
1600AEGQVAAADD
1609 or ANM_S2mut,
1652KISQ-
LAAVDD
1661
) remained cytoplasmic (data not shown).
Also in leukemic cells Taspase1 localizes predominantly to
cellular nucleus and both indicator proteins localize predominant-
ly to the cytoplasm, while co-expression of either indicator protein
and the active protease promotes the indicator protein’s nuclear
accumulation (Figure 2a). Mutation of Thr
234 into Val
(Tasp
T234V) or Asp
233 into Ala (Tasp
D233A) of Taspase1 affected
autoprocessing as well as the protease’s trans-cleavage activity.
Both mutants showed a nuclear but not nucleolar localization, but
in contrast to the wild type protease co-expression of the
catalytically inactive Tasp
T234V- or Tasp
D233A-GFP mutants did
not result in effective cleavage and nuclear translocation of the
indicator proteins. Similar results were obtained upon co-
expression of untagged Tasp
T234V or Tasp
D233A as well as of
their fusions to the red- (mCherry) or blue-fluorescent (BFP)
protein, allowing their independent detection in living cells
Genetic Taspase1 Targeting
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immunoblot analysis (Figure 2b) [6,13].
These results demonstrate the specificity of the assay system for
Taspase1 and underline the advantage of using rational combi-
nations of multi-color autofluorescent proteins to study Taspase1’s
biological activity in living cells. Interestingly, we found that
Tasp
D233A showed cleavage-site specificity, being able to process
ANM_S2R, albeit with a highly attenuated activity, but not
Figure 1. Analyzing Taspase1’s processing of AF4NMLL substrates in living cells. A. Autoproteolysis of the Taspase1 proenzyme is assumed
to trigger formation of the active abba-heterodimer, which hydrolyses the AF4NMLL fusion protein. Following processing, the cleavage products
AF4NMLL.N and MLL.C heterodimerize, forming a high molecular-weight protein complex resistant to degradation. Domain organization of the
AF4NMLL fusion. Taspase1 cleavage sites, S1 (QVDGADD) and S2 (QLDGVDD), are highlighted. NHD: N-terminal homology domain; ALF: AF4/LAF4/
FMR2 homology domain; PHD: plant homeodomain; BrD: bromodomain; FRYN: F/Y rich domain N-terminal; TAD: transactivation domain; FRYC: F/Y
rich domain C-terminal; SET: suppressor of variegation, enhancer of zeste and trithorax. Domains are not drawn to scale. B. Principle of the cell-based
biosensor assay to analyze Taspase1-mediated AF4NMLL processing. The indicator protein localizes predominantly to the cytoplasm but is
continuously shuttling between the nucleus and the cytoplasm. Co-expression of active Taspase1 results in the proteolytic removal of the NES,
thereby triggering nuclear accumulation of the green fluorescent indicator. C–D. Domains of the indicator protein, composed of GST, GFP,
combinations of a nuclear import (?: NLS) and an export (?: NES) signal, combined with the indicated cleavage sites of AF4NMLL. c. ANM_S1/2
containing both cleavage sites is already partially processed by endogenous Taspase1 (left panel), but is completely nuclear upon expression of
Taspase1-BFP (right panel). D. Indicator proteins containing only one cleavage site (ANM_S1 or A NM_S2) are cytoplasmic in their uncleaved state,
whereas ectopic expression of active Taspase1 triggers their cleavage and complete nuclear accumulation. GFP/BFP were visualized by fluorescence
microscopy in living HeLa transfectants 24 h after transfection. Scale bars, 10 mm. Dashed lines mark cytoplasmic/nuclear cell boundaries obtained
from the corresponding phase contrast images.
doi:10.1371/journal.pone.0034142.g001
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autofluorescent proteins have been shown to be fully functional,
we confirmed these results by employing untagged or HA-tagged
Taspase1 variants (data not shown) [23]. Hence, our system is also
applicable to assess Taspase1 trans-cleavage activity on the
individual AF4NMLL cleavage sites independently from each
other.
Targeting Taspase1 Function in Trans by Catalytically
Inactive Mutants
Subsequently, we used the established bioassay to investigate the
consequences of overexpressing catalytically impaired Taspase1
mutants on the activity of the wild type (WT) enzyme in trans.W e
reasoned if inactive Taspase1 mutants are capable of forming
heterodimers with WT Taspase1 (heterodimerization model),
enforced overexpression of these mutants should have a domi-
nant-negative effect. Besides the catalytically dead Tasp
T234V-GFP
mutant, we also included Tasp
D233A-GFP in the analysis, as this
variant exists in a biologically active though highly attenuated
conformation. Notably, our assay demonstrated that even co-
transfecting a nine-fold excess of the Tasp
T234V- or of the
Tasp
D233A-GFP mutants over the WT Taspase1 expression
plasmid did not affect Taspase1’s processing of either the first or
the second AF4NMLL cleavage site in solid as well as in leukemic
cancer cell lines. These results could be independently verified in
several solid as well as leukemic cancer cell lines (Figure 3a/b
and Table 1). Immunoblot analysis confirmed that the mutants
were efficiently overexpressed (Figure 3c). Similar results were
obtained when using HA-tagged or untagged Taspase mutants
(data not shown). To further exclude the formal possibility that our
results are only valid for ectopically expressed Taspase1, we used
the SaOs and SW480 cell lines expressing high levels of
endogenous Taspase1 [23]. Upon expression in these cells, the
ANM_S1/2 indicator protein is already fully or partially cleaved by
endogenous Taspase1 resulting in its predominant nuclear
localization (Figure S1a and Table 1). As expected, overexpres-
sion of the inactive Taspase1 variants did not inhibit the
endogenous enzyme and thus, did not affect cleavage of the
indicator protein in trans (Table 1).
Next, we further analyzed whether cis-cleavage of WT Taspase1
could be affected in trans. As shown in Figure 3d, co-transfection
of the WT protease with GFP-tagged or untagged mutants did not
inhibit Taspase1’s cis-cleavage activity, since the processed
Taspase1 b-subunit was detectable in all plasmid combinations
used. Immunoblot analysis verified that the Tasp
T234V-o r
Tasp
D233A-GFP proenzymes are impaired in their activation by
autoproteolytic cis-cleavage (Figure 3d).
Also, we tested whether overexpression of the individual
Taspase1 a-o rb-subunit, which are clearly proteolytically
inactive, affects Taspase1’s trans cleavage. In line with the results
obtained upon overexpression of full-length inactive Taspase1
variants, no inhibition of Taspase1’s processing was detectable
(Figure S3a/b).
To additionally exclude the possibility that the lack of a trans-
dominant phenotype was restricted to the AF4NMLL protein, we
tested the ability of the mutants to interfere with the processing of
indicator proteins containing the cleavage-sites from the bona fide
Taspase1 targets TFIIA (NLS-mCherry/GST-TFIIA_S-NES=T-
FIIA_SR) and USF2 (NLS-mCherry/GST-USF2_S-NE-
S=USF2_SR) [7]. No inhibition of processing occurred for these
substrates as well as for the full length TFIIA or USF2 proteins
(Table 1).
Analysing Taspase1 Heterocomplex-formation
In general, interruption of pathobiological relevant protein
complexes via enforced expression of trans-dominant negative
mutants critically depends on efficient heterocomplex formation
[9,30]. Thus, the lack of a trans-dominant negative effect upon
overexpression of inactive Taspase1 mutants may be explained by
inefficient heterocomplex formation in vivo. Expression of Tas-
pase1-GFP in bacteria showed protein aggregation (Figure S3c),
which had been previously reported [13]. Co-immunoprecipita-
tion studies of overexpressed Taspase1 and GFP-fusions of the
Taspase1 variants also indicated that the WT protein is in
principle able to interact with biologically impaired mutants
Figure 2. Activity and complex formation of Taspase1 and catalytically inactive mutants. A. Taspase1 processing of AF4NMLL substrates
in leukemic cells. Co-transfection of Tasp-GFP resulted in proteolytic cleavage and nuclear accumulation of the red fluorescent biosensor, ANM_S2R,i n
K562 cells. In contrast, co-expression of Tasp
D233A-GFP leads to partial processing and nuclear translocation, while Tasp
T234V-GFP was completely
inactive. Localization was analyzed 24 h post transfection. GFP/mCherry were visualized by fluorescence microscopy. Scale bars, 10 mm. B. Processing
of AF4NMLL substrates. Co-transfection of Tasp resulted in proteolytic cleavage of the biosensor ANM_S2R in 293T cells as indicated by immunoblot. In
contrast, Tasp
T234V was inactive in cis and trans. Proteins were visualized using a-GST or a-Taspase1 Abs. GapDH served as loading control. fl,
unprocessed Taspase1; Taspb, Taspase1 b-subunit.
doi:10.1371/journal.pone.0034142.g002
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Taspase1 with a bona fide interaction partner, the nucleolar protein
NPM1, the observed interaction was rather weak (Figure S3d)
[23].
To further exclude that these results might be valid only for
ectopically overexpressed Taspase1, we additionally examined the
endogenous protein in MV4;11 human leukemia cells. These cells
were isolated from a patient containing a t(4;11) translocation and
thus, express the AF4NMLL fusion protein, which is processed by
endogenous Taspase1. Employing gel filtration chromatography of
cell lysates isolated under native conditions, we detected endog-
enous Taspase1 predominantly as an ab-monomer (Figure S3e).
Probing Taspase1 Heterocomplex-formation in Living
Cells by a Translocation-based Protein Interaction Assay
Subsequently, we applied a dual color translocation assay that
allows visualization of protein complex formation in living cells
(Figure 4b) to test our hypothesis. This principle has been
successfully employed in several studies to assess protein interac-
tion in living cells, including the t(4;11) leukemia relevant MLL-
FYRN and -FYRC proteins [9,22,23,31]. Here, GFP-tagged
Taspase1 was engineered to localize predominantly to the
cytoplasm by C-terminal fusion of a strong nuclear export signal
(NES) (TaspCyt). Due to Taspase1’s intrinsic nuclear import signal,
TaspCyt is continuously shuttling between the nucleus and the
cytoplasm, and still catalytically active (Figure 4b/c) [23]. The
red-fluorescent Taspase1 variants (Tasp-mCherry, prey) however
Figure 3. Overexpression of inactive Taspase1 mutants does not inhibit Taspase1’s cis- or trans-cleavage activity. A. Cells were
transfected with 1 mgo fA NM_S2R, 0.1 mg Tasp-BFP together with the indicated amounts of inactive Taspase1 mutants or GFP expression plasmid, and
analyzed 24 h later. Even co-transfection of a nine-fold excess of plasmids encoding the inactive Taspase1 variants did not affect ANM_S2R processing
in living HeLa cells. B. The number of HeLa (left panel) or leukemic K562 cells (right panel) showing cytoplasmic (C), cytoplasmic and nuclear (N/C) or
nuclear (N) fluorescence was counted in at least 200 ANM_S2R-expressing cells. Results from one representative experiment of each indicated cell line
are shown. Whereas the number of cell displaying cytoplasmic fluorescence significantly decreased by trans-cleavage upon co-transfection of 0.1 mg
Tasp-BFP expression plasmid (***: p,0.0001), no significant trans-dominant negative effect was evident for Taspase1 mutants. C. Taspase1 trans-
cleavage of ANM_S2R is unaffected by inactive Taspase1 mutants as shown by immunoblot analysis of 293T cells transfected with the indicated
expression plasmids. Proteins and cleavage products were visualized using a-GST and a-Tasp Ab. GapDH served as loading control. D. Cis-cleavage of
Taspase1 is not inhibited by inactive Taspase1 mutants as shown by immunoblot analysis of 293T cells transfected with 1 mg of the indicated
expression plasmids.
doi:10.1371/journal.pone.0034142.g003
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expression and efficient heterocomplex formation, the GFP-tagged
TaspCyt is expected to co-localize with the Tasp-mCherry prey
variants in the nucleus/nucleolus. Therefore, nuclear translocation
serves as a reliable indicator for efficient protein-protein interac-
tion in living cells. This approach allows analyzing complex
formation between the WT and the inactive mutant enzymes
(Figure 4b). Co-expression of the positive control, NPM1-RFP,
significantly triggered nuclear/nucleolar translocation of GFP-
TaspCyt, whereas co-expression of the non-interacting nucleolar
RevM10BL-RFP protein (negative control) showed no effect
(Figure 4d), confirming the assays specificity. As already expected
from the functional data (Figure 3), co-expression of mutant
Taspase1 variants did not result in strong nuclear/nucleolar
translocation of TaspCyt, indicative of only weak heterocomplex
formation (Figure 4d). Similar results were obtained upon
expression of untagged WT or mutant Taspase1 by immunoflu-
orescence analysis in fixed cells (data not shown). To objectively
quantitate the degree of co-localization, we employed confocal
laser scanning microscopy revealing a colocalization R-value of
0.74 for NPM1-RFP, 0.19 for RevM10BL-RFP and R-values of
0.38–0.39 for WT and Taspase1 mutants, respectively (Table S4
and Figure S4). Hence, although WT or mutant Taspase1
variants are in principle able to form (hetero)complexes, these
complexes appear to be rather unstable.
Subsequently, we investigated whether the individual a-o rb-
subunits efficiently bound to WT or mutant Taspase1 variants. We
found that the nuclear Taspase1a-BFP protein (Figure S5a,
upper picture) was unable to efficiently multimerize with TaspCyt
and to recruit it to the nucleus (Figure S5b). Second, co-
expression of Taspase1- or Tasp
T234V-mCherry did not induce
nuclear/nucleolar translocation of Taspb-GFP (Figure S5a,
lower picture and S5c).
Of note, although the subunits were unable to efficiently
interact with full length Taspase1, we though observed hetero-
complex formation when both subunits were co-expressed. As
shown in Figure S5d,T a s p a-BFP or Taspa-HA recruited Taspb-
GFPtothenucleus.Also,anengineeredcytoplasmicTasp-b protein
(Tasp-bCyt), accumulated in the nucleus due to complex formation
with nuclear Taspa-BFP or Taspa-HA (Figure S5e). These results
are somehow unexpected as overexpression of the individual
Taspase1 a-o rb-subunits showed no trans-dominant negative
effect (Figure S3c/d). Thus, we examined whether the complex
formed upon coexpression of the individual subunits resembles
biologically active Taspase1 generated by autoproteolytic cleavage
of the proenzyme. Upon co-expression of Taspa-BFP with Taspb-
GFP neither the AF4NMLL- nor the TFIIA-indicator protein was
cleaved (Figure S5f and data not shown). Similar results were
obtained byco-expressing Taspa-HAwithuntaggedTaspb(datanot
shown). Hence, co-expression of the individual a- and b-subunit
does not allow their assembly into an enzymatically active protease
complex. Formation of the ab-monomer by cis-cleavage of the
proenzyme seems to occur by a regulated step-wise process.
Discussion
Recent advances towards the understanding of cancer system
biology inspired to consider cancer-related protein-protein inter-
action networks as potential therapeutic targets [15,16,17].
Recently, we used our in vivo protein interaction assay to also
demonstrate that it is in principle possible to specifically inhibit the
AF4NMLL oncoprotein by genetic PPIs inhibitors [9]. As the
steady-state amount of the AF4NMLL protein is critically
controlled through its processing by Taspase1, it is tempting to
target the formation of the active protease by interfering with its
multimerization as a novel strategy to block the pathobiological
function of AF4NMLL. However, in order to potentially transfer
such approaches into the clinics it is imperative to know whether
the protein of interest indeed efficiently forms multimers in vivo
causally required for its pathological functions.
Table 1. Effects of overexpressing inactive Taspase1 mutants in trans on Taspase1’s processing of various target proteins.
1 mg indicator +
0.1 mg BFP
+ 0.9 mg GFP
0.1 mg Tasp-BFP
+ 0.9 mg GFP
0.1 mg Tasp-BFP
+ 0.9 mg Tasp
T234V-GFP
0.1 mg Tasp-BFP
+ 0.9 mg Tasp
D233A-GFP
localization C N C N C N C N
ANM_S1R (HeLa) .90% ,1% ,5% .80% ,5% .80% ,5% .80%
ANM_S1R (K652) .85% ,1% ,7% .75% ,7% .75% ,7% .75%
ANM_S2R (HeLa) .90% ,1% ,5% .80% ,5% .80% ,5% .80%
ANM_S2R (K562) .85% ,1% ,5% .80% ,5% .80% ,5% .80%
TFIIA_SR (HeLa) .90% ,1% ,5% .80% ,5% .80% ,5% .80%
USF2_SR (HeLa) .90% ,1% ,5% .80% ,5% .80% ,5% .80%
1 mg BFP 1 mg Tasp
T234V-BFP 1 mg Tasp
D233A-BFP
CNCNCN
ANM_S1/2 (SaOs) ,2% .90% ,2% .90% ,2% .90%
ANM_S1/2 (SW480) ,5% .80% ,5% .80% ,5% .80%
Leukemic (K562) and solid tumor cells were transfected with the indicated amounts of the different indicator plasmids, together with respective control plasmids, or
expression plasmids encoding active or inactive Taspase1 mutants, and analyzed 24 h later. The number of cells showing cytoplasmic (C) or nuclear (N) fluorescence
was counted in at least 200 indicator protein-expressing cells. Results from one representative experiment are shown. Whereas the number of transfectants displaying
cytoplasmic fluorescence, i.e., uncleaved indicator protein, significantly decreased upon co-transfection of 0.1 mg Tasp-BFP expression plasmid (***: p,0.0001), no
inhibition of cleavage was observed even upon co-transfection of 0.9 mg expression plasmids encoding for the inactive Taspase1 mutants.
In transfectants with high (SaOs) or intermediate (SW480) levels of endogenous Taspase1, the ANM_S1/2 indicator protein (0.2 mg expression plasmid) is already fully or
partially cleaved in absence of ectopically expressed protease resulting in its predominant nuclear localization. A similar localization was observed upon co-expression
of the inactive Taspase1 variants (1 mg expression plasmid), indicating that the activity of endogenous Taspase1 is not inhibited in trans.
doi:10.1371/journal.pone.0034142.t001
Genetic Taspase1 Targeting
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e34142For Taspase1 it is assumed that following autoproteolysis of the
zymogen, its subunits assemble into an asymmetric abba-
heterodimer, representing the active protease [6,13]. This model
is mainly based on the crystal structures of other type 2
asparaginases, as well as on the structure obtained from bacterially
expressed Taspase1 [13]. Thus, it was concluded that the enzymes
consist as a four-layered abba structure, with a central, mostly
anti-parallel b-sandwich that is surrounded by a-helices on both
faces [6,13]. However, experimental evidence convincingly
demonstrating that not only Taspase1 but also other type 2
asparaginases do exist in their natural environment as heterodi-
mers, and that multimerization is indeed essential for their
biological activities is still missing. Clearly, the structure resolved
by Khan et al. provided important insights into Taspase1 function,
albeit some limitations may exist [13]. For example, the position of
critical functional domains, such as the bipartite NLS can’t be
deduced from the current computational model of Taspase1 as
these residues are disordered [13,23]. Also, the structure of the
abba-heterodimer was obtained by co-crystallizing the individual
subunits rather than the autoproteolytically processed zymogen.
As shown in our study, co-expression of the individual Taspase1
subunits was unable to assemble into a functional protease in vivo.
Based on our data it is thus conceivable to speculate that in vivo a
complex equilibrium between Taspase1 dimers and already active
ab-monomers might exist (Figure 5). According to the ‘‘hetero-
dimer model’’, the full length Taspase1 zymogen dimerizes, and
upon autoproteolysis assembles into an asymmetric Taspase1abba-
heterodimer, representing the active protease. Hence, Taspase1 is
expected to exist in equilibrium of full length Taspase1 monomers,
unprocessed Taspase1 dimers as well as active processed
Taspase1abba-heterodimers. The Taspase1abba-heterodimers may
further dissociate into free Taspase1a and Taspase1b subunits. The
formation of these forms is regulated by their association (k1) and
dissociation constants (k–1) as well as by the kinetics of
autoproteolysis, which have not been determined yet
(Figure 5a–c).
Interruption of pathobiological relevant protein complexes via
enforced expression of trans-dominant negative mutants has been
employed in several disease models and requires efficient
heterocomplex formation [15,32]. Assuming that inactive Tas-
pase1 variants are capable of interacting efficiently with the wild
type enzyme, a nine-fold overexpression of inactive Taspase1
variants would strongly shift the equilibrium towards the
formation of catalytically impaired heterodimers, resulting in a
significant trans-dominant negative phenotype in vivo. For the cases
reported, inhibition was already evident upon equimolar co-
expression of WT protein and trans-dominant mutants, in contrast
to what we observed for Taspase1 and inactive Taspase1 variants.
Figure 4. Probing Taspase1 multimerization in living cells. A. Heterocomplex formation of Taspase1 and Taspase1 variants shown by co-
immunoprecipitation (IP). IPs of 293T cell extracts co-transfected with the indicated expression constructs were carried out using a-GFP Ab-coated
magnetic beads and m-MACS columns. Precipitated proteins were identified by immunoblot using the indicated antibodies. Input: Total amount of
cell lysate. IP: immunoprecipitated proteins. *: GFP-degradation products [33]. B. Principle of the translocation based protein-protein interaction
assay. The TaspCyt fusion is composed of GFP, Taspase1 and a NES (?) and thus, continuously shuttling between the nucleus and the cytoplasm. The
red-fluorescent Taspase1 variants (Tasp-mCherry prey) accumulate at the nucleus/nucleolus. Upon efficient protein-protein interaction, the GFP-
tagged cytoplasmic TaspCyt co-localizes with the Tasp-mCherry prey to the nucleus/nucleolus in living cells. C. Localization of indicated proteins in
the absence of potential interaction partners. D. Neither co-expression of WT nor inactive Taspase1 variants resulted in strong nuclear/nucleolar
translocation of TaspCyt. Co-expression of NPM1-RFP, known to strongly interact with Taspase1, triggered nuclear/nucleolar translocation of TaspCyt
(positive control). In contrast, co-expression of the non-interacting nucleolar RevM10BL-RFP protein showed no effect (negative control) as visualized
by fluorescence microscopy in living HeLa transfectants. Scale bars, 10 mm.
doi:10.1371/journal.pone.0034142.g004
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untagged-Taspase1 behaves differently [7,23]; this report), we are
aware that the results of the in vivo protein interaction assays might
be affected by the use of Taspase1 variants fused to autofluorescent
proteins.
Alternatively, our data could be interpreted by a ‘‘monomer
model’’, in which the Taspase1ab proenzyme is autoproteolytically
cleaved forming a Taspase1ab monomer, already representing the
active protease (Figure 5d–f). According to this model, the
relative concentrations of these forms and thus, protease activity
are regulated by the kinetics of autoproteolysis. As such, it is
expected that even an excess of inactive Taspase1 variants would
not affect the formation and biological activity of the Taspase1ab
monomers, which is in line with our experimental evidence. Such
a model though does not exclude that the cellular pool is
composed of Taspase1ab monomers as well as Taspase1abba-
heterodimers. Whether such multimerization has additional
biological implications, such as preventing Taspase1 degradation,
conferring cleavage-site selectivity or specificity remains to be
resolved. Theoretically, processed Taspase1ab may also exist in
equilibrium with its subunits. However our observation that co-
expression of the individual a- and b-subunit does not allow their
assembly into an enzymatically active protease complex, argues
against a highly dynamic exchange of the subunits. Hence,
assembly of the ab-monomer by cis-cleavage of the proenzyme
seems to occur by an ordered, stepwise process, which might be
guided by molecular chaperones, such as NPM1 [23]. In line with
our findings, Khan et al. reported significant differences in the
structures obtained by co-expression of the individual Taspase1
subunits versus the full-length enzyme [13].
As one might argue that the catalytically inactive Tasp
T234V
variant is unable to achieve a conformation allowing efficient
complex formation with active Taspase1, we included the highly
attenuated Tasp
D233A mutant in the analysis. The molecular
mechanism explaining why this mutant showed cleavage-site
specificity is not yet resolved. Although this variant thus exists, at
least transiently, in a biologically relevant conformation, we did
not observe an inhibitory effect.
Figure 5. Models illustrating how Taspase1 heterocomplex formation determines the biological effects of overexpressing inactive
Taspase1 mutants. A–C: Heterodimer model - allowing inhibition of Taspase1 function by trans dominant mutants. A. Upon translation, the
Taspase1 zymogen dimerizes and following autoproteolysis matures into an asymmetric Taspase1abba-heterodimer, representing the active protease.
Taspase1 exist in equilibrium of unprocessed Taspase1 monomers, unprocessed Taspase1 dimers, and active processed Taspase1abba-heterodimers.
The Taspase1abba-heterodimers may further dissociate into free Taspase1a and Taspase1b subunits. B. Co-expression of an excess of inactive
Taspase1 variants results in the formation of catalytically impaired heterodimers, reducing the concentration of active Taspase1 molecules. C.
Consequently, AF4NMLL processing is inhibited allowing its degradation by SIAH1/2, thereby preventing the activation of cellular proliferation
programs. D–F: Monomer model - predicting Taspase1’s resistance to enforced expression of inactive mutants. D. The Taspase1ab proenzyme is
autoproteolytically cleaved, forming an active Taspase1ab monomer. The processed Taspase1ab monomer seems to exist also as a Taspase1abba-
heterodimer, and potentially in equilibrium with its subunits. E. Overexpression of inactive Taspase1 variants does not affect the concentration and
activity of Taspase1ab monomers. F. Hence, Taspase1ab monomers are able to cleave the AF4NMLL fusion protein, resulting in the formation of a SIAH-
resistant AF4NMLL complex allowing the activation of target genes driving oncogenesis.
doi:10.1371/journal.pone.0034142.g005
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of biologically inactive Taspase1 mutants as well as of the a-o rb-
subunits does not interfere with Taspase1’s cis- and trans-cleavage
activity; and (ii) complexes formed by the individual Taspase1 a
and b subunit are inactive and do not reflect biologically active
Taspase1 generated by autoproteolytic cleavage of the zymogen.
We are aware that besides the models presented here, our
results may be explained by alternative models, in which the
tetramer only needs one active dimer or has such a high turn over
that the effects are not measurable. Clearly, comprehensive
experimental work is required to discriminate between these
molecular scenarios in vivo. However, this would imply that
targeting Taspase1 heteromultimerization by genetic or chemical
decoys is unlikely to interfere with its (patho)biological activity,
including activation of the AF4NMLL oncoprotein (Figure 5f). As
stabilization of protein complexes by chemical decoys is currently
considered an alternative approach to inhibit disease-relevant
pathways, it is tempting to investigate such an approach also for
Taspase1. Based on our work and studies reported so far, strategies
to dissect and selectively inhibit the (patho)biological activity of
Taspase1 in oncogenesis are still advised to focus on the (high-
throughput) identification of chemicals targeting Taspase1’s
catalytic activity.
Supporting Information
Figure S1 Optimization of indicator proteins to monitor
AF4NMLL processing. A. Nuclear localization of the ANM_S1/2
indicator protein in cancer cell lines expressing high levels of
endogenous Taspase1. B–E. Optimization of the AF4NMLL
cleavage indicator proteins by addition of linker sequences shown
in HeLa cells. Integration of the Taspase1 AF4NMLL recognition
site alone does not allow processing and nuclear accumulation of
the indicator protein by ectopically expressed Taspase1-BFP (B)
Processing was improved by the integration of a GSGS- (C)o r
KIS-linker (D) N-terminal to the cleavage site. The ANM_S2
indicator protein containing the KISQLDGVDDGSGS cleavage
site (spacer sequence underlined) showed optimal performance,
cytoplasmic in the absence of ectopic Taspase1, whereas co-
expression of Taspase1-BFP triggered proteolytic cleavage and
complete nuclear translocation (E). BFP/GFP-fusion was visual-
ized by fluorescence microscopy in living transfectants. Scale bars,
10 mm. Dashed lines mark cytoplasmic/nuclear cell boundaries
obtained from the corresponding phase contrast images.
(PDF)
Figure S2 Taspase1 trans processing of AF4NMLL sub-
strates shows cleavage site-specificity. A. Whereas the
indicator protein ANM_S1R, containing the first cleavage-site from
AF4NMLL, was efficiently processed by Tasp-GFP, both Taspase1
mutants, Tasp
T234V- or Tasp
D233A-GFP, were inactive. B. In
contrast, Tasp
D233A-GFP was able to partially process ANM_S2R,
containing the second cleavage-site from AF4NMLL, whereas
Tasp
T234V-GFP was inactive. Proteins were visualized by fluores-
cence microscopy in living HeLa cell transfected with the indicated
expression plasmids 24 h after transfection. Scale bar, 10 mm. C–
D. Cytoplasmic (C), cytoplasmic and nuclear (N/C) or nuclear (N)
fluorescence was counted in at least 200 ANM_S1R (C)o r
ANM_S2R (D) -expressing HeLa cell co-transfected with the
indicated expression plasmids. Results from a representative
experiment are shown. The number of cells displaying cytoplasmic
fluorescence significantly decreased upon cotransfection of 0.1 mg
Tasp-BFP expression plasmid (***: p,0.0001). Neither
Tasp
T234V- nor Tasp
D233A-GFP cleaved ANM_S1R, but
Tasp
D233A-GFP was able to partially process ANM_S2R, contain-
ing the second AF4NMLL cleavage-site.
(PDF)
Figure S3 A. Expression of GST-Tasp1-GFP (upper panel) in
BL21 bacteria shows extensive protein aggregation. In contrast,
GST-GFP showed no aggregation (lower panel). Images were
taken with identical CCD camera settings. Scale bar, 1 mm. B.
NPM1 strongly interacts with Tasp-GFP. IPs of 293T cell extracts
co-transfected with the indicated expression. Precipitated proteins
were identified by immunoblot using the indicated antibodies.
Input: Total amount of cell lysate. IP: Immunoprecipitated
proteins.
#: GFP-degradation products. C–D. Taspase1 trans-
cleavage is unaffected by overexpression of the Taspase1 a-
subunit. HeLa cells were co-transfected with the indicated
expression plasmid and analyzed 24 h later. C. Even co-
transfection of a nine-fold excess of the nuclear Taspa-GFP did
not affect ANM_S2R processing and its nuclear translocation. The
cleaved red-fluorescent indicator protein, Taspa-GFP, and active
Tasp-BFP fusions were independently visualized by fluorescence
microscopy in living cells. A representative cell is shown. Scale bar,
10 mm. D. The number of cells showing cytoplasmic (C),
cytoplasmic and nuclear (N/C) or nuclear (N) fluorescence was
counted in at least 200 ANM_S2R-expressing cells. Results from a
representative experiment are shown. Whereas the number of cell
displaying cytoplasmic fluorescence significantly decreased upon
co-transfection of 0.1 mg Tasp-BFP expression plasmid, overex-
pression of Taspa-GFP or GFP alone did not inhibit the activity of
Tasp-BFP in trans. E. Endogenous Taspase1 is detectable
predominantly as an ab-monomer. Cell lysates isolated under
native conditions from MV4;11 human leukemia cells were
separated by gel filtration chromatography and resolved by 1D-
SDS PAGE. Immunoblot analysis of FPLC of MV4;11 cell lysates.
Endogenous Taspase1 was visualized in the fractions (49 to
94 kDa) by immunoblot using a-Tasp Ab. *: degradation
products.
(PDF)
Figure S4 Quantitating Taspase1 protein-interaction in
living cells by confocal microscopy. HeLa cells were
transfected with the indicated expression plasmids and protein
localization as well as co-localization analyzed by confocal
microscopy 24 h post transfection. Scale bars, 10 mm. A–B.
Localization of RevM10BL- (negative control), NPM1-RFP
(positive control), TaspCyt, and the red-fluorescent Taspase1
variants (Tasp_mCherry-prey) in the absence of potential
interaction partners in living cells. C–D. Quantitation of protein
co-localization shown as as scatter gram with the gained Manders
overlap coefficient indicated (R values). C. Co-expression of
RevM10BL-RFP had no effect on TaspCyt localization
(R=0.1928), whereas efficient nuclear/nucleolar translocation
was observed upon co-expression of NPM1-RFP (R=0.7354). D.
In contrast, neither co-expression of WT (R=0.3867) nor mutant
Taspase1 variants (Tasp
D233A-mCherry, R=0.3942; Tasp
T234V-
mCherry, R=0.3876) resulted in strong nuclear/nucleolar
translocation of TaspCyt, indicative of only weak heterocomplex
formation in living cells.
(PDF)
Figure S5 Translocation assay to analyze complex
formation of Taspase1 subunits. A–C. The Taspase1 a-o r
b-subunits do not form stable heterocomplexes with WT
Taspase1. A. Localization of Taspase1 a-o rb-subunits in HeLa
transfectants. Taspa-BFP localizes to the nucleus, whereas Taspb-
GFP is nuclear and cytoplasmatic. B. Co-expression of Taspa-BFP
did not trigger nuclear/nucleolar translocation of full length
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e34142TaspCyt. C. Also, co-expression of nuclear/nucleolar Tasp-mCh
did not translocate Taspb-GFP to the nucleolus. Autofluorescent
fusion proteins were visualized in the same cells by fluorescence
microscopy. D–E. Co-expression of the isolated Taspase1 subunits
results in complex formation. D. Upon co-expression, nuclear
Taspa-BFP associates with Taspb-GFP and recruits to the nucleus.
E. Also, a cytoplasmatic GFP-Taspb protein (Tasp-bCyt), gener-
ated by fusion of a strong nuclear export signal (left panel),
accumulated in the nucleus by binding to nuclear Taspa-BFP
(right panel). F. Upon co-expression the isolated Taspase1
subunits do not assemble into an enzymatically active protease
complex. Co-expression of Taspa-BFP with Taspb-GFP does not
result in processing of the ANM_S2R indicator protein. The
uncleaved red-fluorescent indicator protein, Taspa-BFP, and
Taspb-GFP were independently visualized by fluorescence mi-
croscopy in living cells. A representative cell is shown. Scale bar,
10 mm.
(PDF)
Table S1 List of described disease-associated MLL
fusions. Abbreviations: ALL, acute lymphoblastic leukemia;
AML, acute myeloid leukemia; CML, chronic myeloid leukemia;
JMML, juvenile myelomonocytic leukemia; AUL/ANL, acute
undifferentiated leukemia/acute nonlymphocytic leukemia; MDS,
myelodysplastic syndromes; tALL/tAML/tMDS, therapy related
ALL/AML/MDS; tT-ALL, therapy related T-cell ALL. X:
indicates the presence of a putative Taspase1 cleavage site, based
on the Taspase1 recognition sequence
(Q
3[F,I,L,V]
2D
1QG
1’x
2’D
3’D
4’) [1].
(PDF)
Table S2 List of plasmids used in the study. Plasmid
name, encoded protein, and function are indicated. *: tag used for
detection.
(PDF)
Table S3 Oligonucleotides used for PCR amplification
and cloning. Oligonucleotide name and nucleotide sequence are
indicated.
(PDF)
Table S4 Quantitation of Taspase1 heterocomplex
formation by confocal laser scanning microscopy in
living cells. HeLa cells were co-transfected with 1 mg of TaspCyt
and 1 mg of the indicated mCherry-prey expression plasmids, and
analyzed 24 h later. Colocalization coefficients as an indicator of
complex formation were calculated using the colocalizer pro
software. Rr, Pearson’s correlation coefficient; R, overlap
coefficient according to Manders; k1/k2, overlap coefficients;
m1/m2, colocalization coefficients. Results from a representative
experiment are shown. A colocalization R-value of 0.74 for
NPM1-RFP with TaspCyt indicates 74% of colocalization.
(PDF)
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